Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock

• Status: Recruiting
• Trial end date: 2023-12-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of study is this to evaluate the efficacy and safety of continuous linezolid infusion versus the standard regimen in treating critically ill patients with septic shock in the ICU

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Linezolid

Criteria

Inclusion Criteria:

• adult patients aged > 18 years old

• diagnosis of septic shock (patient with septic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial blood pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\L (>18 mg\dL) in the absence of hypovolemia).

• positive culture confirming linezolid susceptibility.

Exclusion Criteria:

• Patient refusal.

• Known allergy to linezolid.

• Pregnancy and lactation.

• Severe hepatic failure (Child-Pugh C).

• Thrombocytopenia (platelet count < 80,000/mm3).

• Disseminated intravascular coagulation (DIC).

• Hematologic disease, and concurrent use of other medications that may interact with linezolid (i.e., macrolides, serotonin modulators), or drug-associated thrombocytopenia.